Tagrisso (Osimertinib) Approved For Advanced Lung Cancer, Available Immediately At Biologics, Inc. (NC)
Published: Nov 17, 2015
CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., is pleased to announce that it has been selected by AstraZeneca as a specialty pharmacy provider for Tagrisso (osimertinib). Tagrisso was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration, and was approved on November 13, 2015, for the treatment of advanced lung cancer.
“We are happy to be included as a network partner for this breakthrough therapy and feel that our personal care plan model will greatly benefit the patients in need of Tagrisso”
“We are happy to be included as a network partner for this breakthrough therapy and feel that our personal care plan model will greatly benefit the patients in need of Tagrisso,” said Shayne Malone, Vice President, Biopharma Services at Biologics.
Physicians may submit prescriptions to Biologics via phone (800.850.4306, option 2), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
- Pharmacy name: Biologics
- Street address: 120 Weston Oaks Court, Cary, NC 27513
- NCPDP: 3430369
- NPI: 1487640314
Biologics takes a high-touch approach to patient care, providing a dedicated team to each individual patient. This multidisciplinary team includes a pharmacist, nurse and patient assistance specialist who work together to support the clinical, financial, and emotional needs of the patient throughout their cancer journey.
Individualized care plans are created for each patient to help them manage side effects, adhere to therapy and provide additional information to them about their disease.
The team also helps alleviate the financial burden for patients. To date, Biologics has raised over $22 million in 2015 for over 7,000 cancer patients. The latest independent survey shows 96% of patients reported they had an exceptional overall experience with Biologics.
About Biologics: Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities, while providing clinical outcomes and informatics reporting that allow for informed decision making. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. Visit biologicsinc.com or follow us on Twitter (@BiologicsInc).